20:41 , Jan 18, 2019 |  BC Week In Review  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
23:21 , Jan 17, 2019 |  BC Extra  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
15:32 , Jun 8, 2018 |  BioCentury  |  Finance

Pfizer plugs back in

While Pfizer Inc. (NYSE:PFE) retreated from neuroscience R&D in January, the pharma hasn’t cut the cord yet. Ramped up allocations to neuroscience out of its latest $600 million venture investment give Pfizer the ability to...
15:17 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Pfizer allocates $600M to venture, with neuroscience a focus

Pfizer Inc. (NYSE:PFE) on June 6 said it will invest $600 million in biotech and other emerging growth companies via Pfizer Ventures, with about $150 million devoted to early stage neuroscience companies. Pfizer said initial...
12:01 , Jun 6, 2018 |  BC Extra  |  Financial News

Pfizer allocates $600M to venture, with neuroscience a focus

Pfizer Inc. (NYSE:PFE) said it will invest $600 million in biotech and other emerging growth companies via Pfizer Ventures, with about $150 million devoted to early stage neuroscience companies. Pfizer said initial areas of interest...
19:00 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...
20:23 , Dec 22, 2017 |  BC Week In Review  |  Company News

Boehringer, Autifony in deal for potassium channel modulators

Autifony Therapeutics Ltd. (Stevenage, U.K.) granted Boehringer Ingelheim GmbH (Ingelheim, Germany) an exclusive option to acquire its potassium channel Kv3.1 (KCNC1)/KCNC2 modulator program. Autifony will receive €25 million ($29.5 million) up front and is eligible...
22:29 , Dec 18, 2017 |  BC Extra  |  Company News

Boehringer, Autifony in deal for potassium channel modulators

Autifony Therapeutics Ltd. (Stevenage, U.K.) granted Boehringer Ingelheim GmbH (Ingelheim, Germany) an exclusive option to acquire its potassium channel Kv3.1 (KCNC1)/KCNC2 modulator program. Autifony will receive €25 million ($29.5 million) up front and is eligible...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
15:01 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

Autifony begins Phase Ib of AUT00206 in schizophrenia

Autifony Therapeutics Ltd. (Stevenage, U.K.) began a double-blind, placebo-controlled, U.K. Phase Ib trial of twice-daily 800 mg oral AUT00206 for 4 weeks as adjunctive therapy in about 24 recently diagnosed schizophrenic patients. The trial is...